share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股sec公告 ·  04/16 16:12
Moomoo AI 已提取核心訊息
bluebird bio, Inc. has announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company had previously filed a Form 12b-25 with the Securities and Exchange Commission, which granted a 15-day extension until April 16, 2024, for the filing. However, due to the time required to complete the necessary procedures for restating its consolidated financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of both 2023 and 2022, bluebird bio will not meet the extended deadline. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements. The company is working to finalize the 2023 Form 10-K as soon as possible and anticipates a delay in filing its Quarterly Report on Form 10-Q for the first quarter of 2024 as well. bluebird bio has stated that the restatements are not expected to affect its cash position or revenue.
bluebird bio, Inc. has announced a delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company had previously filed a Form 12b-25 with the Securities and Exchange Commission, which granted a 15-day extension until April 16, 2024, for the filing. However, due to the time required to complete the necessary procedures for restating its consolidated financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of both 2023 and 2022, bluebird bio will not meet the extended deadline. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements. The company is working to finalize the 2023 Form 10-K as soon as possible and anticipates a delay in filing its Quarterly Report on Form 10-Q for the first quarter of 2024 as well. bluebird bio has stated that the restatements are not expected to affect its cash position or revenue.
藍鳥生物公司宣佈延遲提交截至2023年12月31日財年的10-K表年度報告。該公司此前曾向美國證券交易委員會提交了12b-25表格,該委員會批准將申報期限延長15天,至2024年4月16日。但是,由於完成重報截至2022年12月31日止年度的合併財務報表的必要程序以及2023年和2022年前三個季度的未經審計的財務信息需要時間,藍鳥生物將無法在延長的截止日期之前完成。重報與確定嵌入式租賃和對租賃協議中非租賃部分的處理有關。該公司正在努力盡快完成2023年10-K表格,並預計延遲提交2024年第一季度的10-Q表季度報告。藍鳥生物表示,重報預計不會影響其現金狀況或收入。
藍鳥生物公司宣佈延遲提交截至2023年12月31日財年的10-K表年度報告。該公司此前曾向美國證券交易委員會提交了12b-25表格,該委員會批准將申報期限延長15天,至2024年4月16日。但是,由於完成重報截至2022年12月31日止年度的合併財務報表的必要程序以及2023年和2022年前三個季度的未經審計的財務信息需要時間,藍鳥生物將無法在延長的截止日期之前完成。重報與確定嵌入式租賃和對租賃協議中非租賃部分的處理有關。該公司正在努力盡快完成2023年10-K表格,並預計延遲提交2024年第一季度的10-Q表季度報告。藍鳥生物表示,重報預計不會影響其現金狀況或收入。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息